| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Arch Venture Fund XIII LP | 10% Owner | 2026-03-06 | 488,090 | $25.61 | $12.50MBuy |
| Arch Venture Partners IX LLC | 10% Owner | 2026-03-06 | 488,090 | $25.61 | $12.50MBuy |
| Lynn Seely | President and CEO | 2026-02-11 | 7,455 | $23.39 | $174.37kSell |
| Stephen J. Hill | Chief Operating Officer | 2026-02-11 | 1,236 | $23.39 | $28.91kSell |
| Gary K. Lee | Chief Scientific Officer | 2026-02-11 | 1,671 | $23.39 | $39.08kSell |
| Veronica Sanchez Bulis | VP Corporate Controller | 2026-02-10 | 254 | $23.12 | $5.87kSell |
| Stephen J. Hill | Chief Operating Officer | 2026-02-10 | 109 | $23.12 | $2.52kSell |
| Lynn Seely | President and CEO | 2026-02-10 | 438 | $23.12 | $10.13kSell |
| Gary K. Lee | Chief Scientific Officer | 2026-02-10 | 147 | $23.12 | $3.40kSell |
| Veronica Sanchez Bulis | VP Corporate Controller | 2025-12-30 | 936 | $32.32 | $30.25kSell |
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Robert Nelsen | 234.07% | 54,619,074 | $693.66M | Insider |
| Arch Venture Partners IX LLC | 167.75% | 39,143,667 | $497.12M | Insider |
| Glaxosmithkline PLC | 129.65% | 30,253,189 | $384.22M | Insider |
| Richard Klausner | 39.69% | 9,262,406 | $117.63M | Insider |
| Hans Edgar Bishop | 20.08% | 4,685,614 | $59.51M | Insider |
| Arch Venture Management LLC | 13.92% | 3,247,162 | $41.24M | Institution |
| Arch Venture Fund XIII LP | 7.92% | 1,848,755 | $23.48M | Insider |
| Gsk PLC | 6.48% | 1,512,659 | $19.21M | Institution |
| Foresite Capital Management IV LLC | 3.43% | 800,399 | $10.17M | Institution |
| Orland Properties Ltd | 3.23% | 754,698 | $9.58M | Institution |